Vascular involvement in the pathogenesis of idiopathic inflammatory myopathies

Autoimmunity

Volumn 42, Issue 7, 2009, Pages 615-626

  Grundtman, Cecilia ^a,b   Lundberg, Ingrid E ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; Endothelial cells; Hypoxia; Inflammation; Myositis

Indexed keywords

ANGIOGENESIS; COMPLEMENT ACTIVATION; EXERCISE; HYPOXEMIA; IDIOPATHIC INFLAMMATORY MYOPATHY; INFLAMMATION; MICROCIRCULATION; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYOSITIS; PATHOGENESIS; REVIEW; VASCULAR DISEASE;

ANOXIA; BLOOD VESSELS; CELL ADHESION MOLECULES; COMPLEMENT ACTIVATION; CYTOKINES; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MUSCLES; MYOSITIS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR CELL ADHESION MOLECULE-1;

EID: 71049133435     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930903002511     Document Type: Review

References (67)

1. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16(2):193-208.
2. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984;16(2):209-215.
3. Goncalves FG, Chimelli L, Sallum AM, Marie SK, Kiss MH, Ferriani VP. Immunohistological analysis of CD59 and membrane attack complex of complement in muscle in juvenile dermatomyositis. J Rheumatol 2002;29(6):1301-1307.
4. Sewry CA, Dubowitz V, Abraha A, Luzio JP, Campbell AK. Immunocytochemical localisation of complement components C8 and C9 in human diseased muscle. The role of complement in muscle fibre damage. J Neurol Sci 1987;81(2-3):141-153.
5. Komiya T, Negoro N, Kondo K, Miura K, Hirota Y, Yoshikawa J. Clinical significance of von Willebrand factor in patients with adult dermatomyositis. Clin Rheumatol 2005; 24(4):352-357.
6. Guzman J, Petty RE, Malleson PN.Monitoring disease activity in juvenile dermatomyositis: The role of vonWillebrand factor and muscle enzymes. J Rheumatol 1994;21(4):739-743.
7. Ganczarczyk ML, Lee P, Armstrong SK. Nailfold capillary microscopy in polymyositis and dermatomyositis. Arthritis Rheum 1988;31(1):116-119.
8. Wargula JC, Lovell DJ, Passo MH, Bove KE, Santangelo JD, Levinson JE. What more can we learn from muscle histopathology in children with dermatomyositis/polymyositis? Clin Exp Rheumatol 2006;24(3):333-343.
9. Bartoccioni E, Gallucci S, Scuderi F, Ricci E, Servidei S, Broccolini A, Tonali P. MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clin Exp Immunol 1994;95(1): -1172.
10. Cid MC, Grau JM, Casademont J, Tobias E, Picazo A, Coll-Vinent B, Esparza J, Pedrol E, Urbano-Marquez A. Leucocyte/endothelial cell adhesion receptors inmuscle biopsies from patients with idiopathic inflammatory myopathies (IIM). Clin Exp Immunol 1996;104(3):467-473.
11. De Bleecker JL, Engel AG. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994;53(4):369-376.
12. Tews DS, Goebel HH. Expression of cell adhesion molecules in inflammatory myopathies. J Neuroimmunol 1995;59(1-2): -1194.
13. Sallum AM, Kiss MH, Silva CA, Wakamatsu A, Vianna MA, Sachetti S, Marie SK. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev 2006;5(2):93-100.
14. Sallum AM, Marie SK,Wakamatsu A, Sachetti S, Vianna MA, Silva CA, Kiss MH. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. J Rheumatol 2004;31(4):801-807.
15. Englund P, Nennesmo I, Klareskog L, Lundberg IE. Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: Important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 2002;46(4):1044-1055.
16. Kumamoto T, Abe T, Ueyama H, Sugihara R, Shigenaga T, Tsuda T. Elevated soluble intercellular adhesion molecules-1 in inflammatory myopathy. Acta Neurol Scand 1997;95(1): -137.
17. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147(11):3788-3793.
18. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994; 76(2):301-314.
19. Rice GE, Munro JM, Corless C, Bevilacqua MP. Vascular and nonvascular expression of INCAM-110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissues. Am J Pathol 1991;138(2):385-393.
20. Schlegel PG, Vaysburd M, Chen Y, Butcher EC, Chao NJ. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J Immunol 1995;155(8):3856-3865.
21. Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 1990;144(12):4579-4586.
22. Lindvall B, Dahlbom K, Henriksson KG, Srinivas U, Ernerudh J. The expression of adhesion molecules in muscle biopsies: The LFA-1/VLA-4 ratio in polymyositis. Acta Neurol Scand 2003;107(2):134-141.
23. van Dinther-Janssen AC, Horst E, Koopman G, NewmannW, Scheper RJ, Meijer CJ, Pals ST, The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol 1991;147(12): -14210.
24. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000;43(2):336-348.
25. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: A quantitative study. Ann Neurol 1990;27(4):343-356.
26. Dalakas MC. Polymyositis, dermatomyositis and inclusionbody myositis. N Engl J Med 1991;325(21):1487-1498.
27. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986;314(6):329-334.
28. IsenbergDA. Immunoglobulin deposition in skeletal muscle in primary muscle diseases. Q J Med 1983;52(207):297-310.
29. Cervera R, Ramirez G, Fernandez-Sola J, D'Cruz D, Casademont J, Grau JM, et al. Antibodies to endothelial cells in dermatomyositis: Association with interstitial lung disease. BMJ 1991;302(6781):880-881.
30. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989;84(6):1974-1981.
31. Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, Ziza JM, Godeau P. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients. Am J Med 1991;91(2):162-168.
32. Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirtyfive adult patients. Arthritis Rheum 2002;46(2):467-474.
33. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl JMed 1993;329(27):1993-2000.
34. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94(5):1729- 1735.
35. Barbasso Helmers S, Dastmalchi M, Alexanderson H, Nennesmo I, Esbjornsson M, Lindvall B, Lundberg IE. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis 2007;66(10):1276-1283.
36. El Awad B, Kreft B,Wolber EM, Hellwig-Burgel T, Metzen E, Fandrey J, Jelkmann W. Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int 2000;58(1):43-50.
37. Falanga V, Qian SW, Danielpour D, Katz MH, Roberts AB, Sporn MB. Hypoxia upregulates the synthesis of TGF-beta 1 by human dermal fibroblasts. J Invest Dermatol 1991;97(4): -1637.
38. Salven P, Hattori K, Heissig B, Rafii S. Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J 2002;16(11):1471-1473.
39. Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J, Wolitzky BA, Norton C, Plocinski J, Benjamin W, Burns DK, Goldstein A, Stern D. Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992;90(6): -12339.
40. Chung YL,Wassif WS, Bell JD, Hurley M, Scott DL. Urinary levels of creatine and other metabolites in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) 2003;42(2):298-303.
41. Olsen NJ, Park JH. MRS and NIRS for muscle disease evaluation. Bull Rheum Dis 1995;44(5):4-7.
42. Park JH, Kari S, King LE, Jr, Olsen NJ. Analysis of 31P MR spectroscopy data using artificial neural networks for longitudinal evaluation of muscle diseases: Dermatomyositis. NMR Biomed 1998;11(4-5):245-256.
43. Park JH, Vital TL, Ryder NM, Hernanz-Schulman M, Partain CL, Price RR, Olsen NJ. Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994;37(5): -1746.
44. Ogawa S, Shreeniwas R, Butura C, Brett J, Stern DM. Modulation of endothelial function by hypoxia: Perturbation of barrier and anticoagulant function, and induction of a novel factor X activator. Adv Exp Med Biol 1990;281:303-312.
45. Carry MR, Ringel SP, Starcevich JM. Distribution of capillaries in normal and diseased human skeletal muscle. Muscle Nerve 1986;9(5):445-454.
46. Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: A distinct variety of idiopathic inflammatory myopathy. Neurology 1978;28(1):8-17.
47. De Visser M, Emslie-Smith AM, Engel AG. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989;94(1-3):181-192.
48. Girard JP, Springer TA. High endothelial venules (HEVs): Specialized endothelium for lymphocyte migration. Immunol Today 1995;16(9):449-457.
49. Lundberg I, Ulfgren AK, Nyberg P, AnderssonU, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40(5):865-874.
50. Jerusalem F, Rakusa M, Engel AG, MacDonald RD. Morphometric analysis of skeletal muscle capillary ultrastructure in inflammatory myopathies. J Neurol Sci 1974;23(3): -1402.
51. Vlodavsky EA, Ludatscher RM, Sabo E, Kerner H. Evaluation of muscle capillary basement membrane in inflammatory myopathy. A morphometric ultrastructural study. Virchows Arch 1999;435(1):58-61.
52. Norton WL, Hurd ER, Lewis DC, Ziff M. Evidence of microvascular injury in scleroderma and systemic lupus erythematosus: Quantitative study of the microvascular bed. J Lab Clin Med 1968;71(6):919-933.
53. Finol HJ, Montagnani S, Marquez A, Montes de Oca I, Muller B. Ultrastructural pathology of skeletal muscle in systemic lupus erythematosus. J Rheumatol 1990;17(2): -1219.
54. Vianna MA, Borges CT, Borba EF, Caleiro MT, Bonfa E, Marie SK. Myositis in mixed connective tissue disease: A unique syndrome characterized by immunohistopathologic elements of both polymyositis and dermatomyositis. Arq Neuropsiquiatr 2004;62(4):923-934.
55. Niinikoski J, Paljarvi L, Laato M, Lang H, Panelius M. Muscle hypoxia in myositis. J Neurol Neurosurg Psych 1986;49(12): 1455.
56. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246(4935): -11312.
57. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246(4935):1306-1309.
58. Konttinen YT, Mackiewicz Z, Povilenaite D, Sukura A, Hukkanen M, Virtanen I. Disease-associated increased HIF-1, alphavbeta3 integrin, and Flt-1 do not suffice to compensate the damage-inducing loss of blood vessels in inflammatory myopathies. Rheumatol Int 2004;24(6):333-339.
59. Grundtman C, Tham E, Ulfgren AK, Lundberg IE. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum 2008;58(10):3224-3238.
60. Hollemann D, Budka H, Loscher WN, Yanagida G, Fischer MB, Wanschitz JV. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis 2006;3:2.
61. HollemannD,BudkaH,LoscherWN,YanagidaG, FischerMB, Wanschitz JV. Endothelial and myogenic differentiation of hematopoietic progenitor cells in inflammatory myopathies. J Neuropathol Exp Neurol 2008;67(7):711-719.
62. Gollnick PD, Saltin B. Significance of skeletal muscle oxidative enzyme enhancement with endurance training. Clin Physiol 1982;2(1):1-12.
63. Lundberg IE, Nader GA. Molecular effects of exercise in patients with inflammatory rheumatic disease. Nat Clin Pract Rheumatol 2008;4(11):597-604.
64. Dastmalchi M, Alexanderson H, Loell I, Stahlberg M, Borg K, Lundberg IE, Esbjornsson M. Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum 2007; 57(7):1303-1310.
65. Hildebrand IL, Sylven C, Esbjornsson M, Hellstrom K, Jansson E. Does chronic hypoxaemia induce transformations of fibre types? Acta Physiol Scand 1991;141(3):435-439.
66. Simoneau JA, Lortie G, Boulay MR, Thibault MC, Theriault G, Bouchard C. Skeletal muscle histochemical and biochemical characteristics in sedentary male and female subjects. Can J Physiol Pharmacol 1985;63(1):30-35. (Pubitemid 15148314)
67. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005;98(4):1154-1162.